U.S. Stem Cell, Inc. (USRM) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
U.S. Stem Cell, Inc. (USRM) trades at $0.0001. U. S. Stem Cell, Inc. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for USRM: USRM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates USRM against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
USRM: 2/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →U.S. Stem Cell, Inc. (USRM) Healthcare & Pipeline Overview
U.S. Stem Cell, Inc. is a biotechnology firm specializing in autologous cellular therapies for chronic and acute heart damage, vascular, and autoimmune diseases. Their pipeline includes MyoCell and AdipoCell therapies, targeting heart failure and ischemia, alongside cell therapy training and storage services, positioning them within the regenerative medicine sector.
What Is the Investment Thesis for USRM?
U.S. Stem Cell, Inc. presents a high-risk, high-reward investment profile within the biotechnology sector. The company's focus on autologous cellular therapies for chronic diseases addresses a significant unmet medical need. Key value drivers include the successful clinical development and commercialization of MyoCell and AdipoCell. However, the company's negative P/E ratio of -0.02 and a substantial negative profit margin of -3483.2% indicate significant financial challenges. Growth catalysts depend on positive clinical trial outcomes and regulatory approvals, particularly for their lead product candidates. Investors should carefully consider the risks associated with OTC-listed companies and the uncertainty inherent in biotechnology investments before considering USRM.
Based on FMP financials and quantitative analysis
USRM Key Highlights
Market capitalization of $0.00B indicates a micro-cap company with limited resources.
- Negative P/E ratio of -0.02 reflects the company's current lack of profitability.
- Gross margin of 71.0% suggests strong potential for profitability if sales volume increases.
- Profit margin of -3483.2% highlights significant operational inefficiencies and high expenses.
- Beta of -48.37 indicates an inverse correlation with the market, but this should be viewed cautiously due to the company's financial instability and OTC status.
Who Are USRM's Competitors?
USRM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are USRM's Key Strengths?
Proprietary autologous cell therapy technologies.
- Specialized training programs in regenerative medicine.
- Established cell therapy clinic for direct patient treatment.
- Focus on unmet medical needs in chronic diseases.
What Are USRM's Weaknesses?
Negative profitability and high operating expenses.
- Limited financial resources and market capitalization.
- Dependence on successful clinical trial outcomes.
- OTC listing with associated risks.
What Could Drive USRM Stock Higher?
Publication of clinical trial results for MyoCell in treating chronic heart failure.
- Regulatory approval decisions for AdipoCell in treating myocardial infarction.
- Expansion of cell therapy clinic services to new geographic locations.
- Strategic partnerships for technology development and commercialization.
- Increased adoption of regenerative medicine training programs by physicians.
What Are the Key Risks for USRM?
Clinical trial failures or negative results for MyoCell and AdipoCell.
- Regulatory delays or rejection of marketing applications.
- Competition from larger biotechnology companies with greater resources.
- Limited financial resources and dependence on external funding.
- Dilution from future capital raises to fund operations.
What Are the Growth Opportunities for USRM?
- Expansion of Cell Therapy Clinic Services: U.S. Stem Cell, Inc. can expand its cell therapy clinic services to cater to a broader range of diseases, including neurological, autoimmune, and orthopedic conditions. The market for regenerative medicine is projected to reach $124.9 billion by 2030, offering a substantial growth opportunity. By enhancing its service offerings and geographic reach, the company can attract more patients and increase revenue. This expansion can be achieved within the next 2-3 years with strategic investments in infrastructure and marketing.
- Strategic Partnerships for Technology Development: Collaborating with research institutions and other biotechnology companies to accelerate the development of MyoCell SDF-1 and MyoCath. Strategic alliances can provide access to advanced technologies, funding, and expertise, reducing development timelines and costs. The global biotechnology market is expected to reach $3.87 trillion by 2030, creating ample opportunities for partnerships. These partnerships could materialize within the next 1-2 years, contingent on successful negotiations and alignment of strategic goals.
- Increased Focus on Veterinary Applications: Leveraging its cell collection and treatment kits for animals to tap into the growing veterinary regenerative medicine market. The veterinary regenerative medicine market is projected to reach $460 million by 2028, driven by increasing pet ownership and demand for advanced veterinary care. By expanding its product offerings and distribution channels, the company can capitalize on this trend. This expansion can be implemented within the next year with targeted marketing and product development efforts.
- Geographic Expansion of Training Programs: Extending its physician and patient-based regenerative medicine/cell therapy training programs to international markets. The global market for medical education is expected to grow, driven by increasing demand for specialized training in advanced medical technologies. By offering training programs in key international markets, the company can generate additional revenue and establish a global presence. This expansion can be phased in over the next 3-5 years, starting with regions with high demand for regenerative medicine.
- Development of New Cell-Based Therapies: Investing in research and development to expand its pipeline of cell-based therapies for other chronic diseases. The market for cell therapies is projected to grow significantly, driven by advancements in cell engineering and delivery technologies. By developing new therapies for conditions such as diabetes, arthritis, and neurodegenerative diseases, the company can diversify its product portfolio and increase its long-term growth potential. This development process typically takes 5-7 years, requiring sustained investment in research and clinical trials.
What Are USRM's Competitive Advantages?
- Proprietary autologous cell therapy technologies.
- Specialized training programs in regenerative medicine.
- Established cell therapy clinic for direct patient treatment.
- Intellectual property related to MyoCell and AdipoCell therapies.
What Does USRM Do?
U.S. Stem Cell, Inc., originally incorporated as Bioheart, Inc. in 1999 and rebranded in 2015, is a biotechnology company headquartered in Sunrise, Florida. The company focuses on the discovery, development, and commercialization of autologous cellular therapies, utilizing a patient's own cells to treat various conditions. Their primary therapeutic areas of interest include chronic and acute heart damage, vascular diseases, and autoimmune disorders. The company's lead product candidates are MyoCell and AdipoCell. MyoCell is designed to regenerate damaged heart tissue in patients with chronic heart failure by populating scar tissue with autologous muscle cells. AdipoCell is a patient-derived cell therapy targeting acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. The company is also developing MyoCell SDF-1, an autologous muscle-derived cellular therapy aimed at improving cardiac function in chronic heart failure patients. Additionally, they are working on MyoCath, a deflecting tip needle injection catheter for precise cell delivery into cardiac tissue during therapeutic procedures. Beyond therapeutic development, U.S. Stem Cell, Inc. provides regenerative medicine and cell therapy training for physicians and patients. They also offer cell collection and storage services, as well as cell collection and treatment kits for both humans and animals. The company operates a cell therapy clinic that provides cellular treatments for patients suffering from neurological, autoimmune, orthopedic, and degenerative diseases, expanding their reach within the regenerative medicine market.
What Products and Services Does USRM Offer?
- Develop autologous cellular therapies for chronic and acute heart damage.
- Create cell therapies for vascular and autoimmune diseases.
- Offer MyoCell therapy to regenerate damaged heart tissue.
- Provide AdipoCell therapy for myocardial infarction and ischemia.
- Develop MyoCell SDF-1 therapy for chronic heart failure.
- Design MyoCath, a needle injection catheter for cell delivery into cardiac tissue.
- Offer regenerative medicine and cell therapy training for physicians and patients.
- Provide cell collection and storage services for humans and animals.
How Does USRM Make Money?
- Develop and commercialize autologous cellular therapies.
- Provide cell therapy training and education services.
- Offer cell collection and storage services.
- Operate a cell therapy clinic providing cellular treatments.
What Industry Does USRM Operate In?
U.S. Stem Cell, Inc. operates within the rapidly evolving biotechnology industry, specifically in the regenerative medicine and cell therapy segment. This sector is characterized by high growth potential, driven by increasing demand for innovative treatments for chronic diseases. However, it is also highly competitive, with numerous companies vying for market share. U.S. Stem Cell competes with larger, more established biotechnology firms, as well as smaller companies focused on niche areas within cell therapy. The success of companies like U.S. Stem Cell depends on their ability to secure regulatory approvals, demonstrate clinical efficacy, and establish strong commercial partnerships.
Who Are USRM's Key Customers?
- Patients with chronic and acute heart damage.
- Patients with vascular and autoimmune diseases.
- Physicians seeking training in regenerative medicine.
- Veterinarians seeking cell therapy solutions for animals.
Key Financial Metrics
Return on equity for U.S. Stem Cell, Inc. stands at 20.8%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
U.S. Stem Cell, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Sunrise, US. The company is led by CEO Michael Tomas. USRM has traded publicly since 2008.
Financial Health
U.S. Stem Cell, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
Insider Activity
The most recent 12 insider filings for U.S. Stem Cell, Inc. break down as 0 sales and 12 purchases. On net that is roughly 71.9M shares acquired (about $759K) — insiders putting money in tends to read as conviction.
USRM Financials
Bull Case vs Bear Case
Bull Case
- Proprietary autologous cell therapy technologies.
- Specialized training programs in regenerative medicine.
- Established cell therapy clinic for direct patient treatment.
- Focus on unmet medical needs in chronic diseases.
Bear Case
- Negative profitability and high operating expenses.
- Limited financial resources and market capitalization.
- Dependence on successful clinical trial outcomes.
- OTC listing with associated risks.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
USRM Latest News
No recent news available for USRM.
USRM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for USRM.
Price Targets
Wall Street price target analysis for USRM.
USRM MoonshotScore
What does this score mean?
The MoonshotScore rates USRM 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Michael Tomas
CEO
Michael Tomas serves as the CEO of U.S. Stem Cell, Inc. His background includes experience in the biotechnology and healthcare sectors. Specific details regarding his prior roles and educational background are not available in the provided data. However, as CEO, he is responsible for the overall strategic direction and operational management of the company.
Track Record: Under Michael Tomas's leadership, U.S. Stem Cell, Inc. has focused on advancing its autologous cell therapy programs, including MyoCell and AdipoCell. Key milestones include ongoing clinical trials and efforts to expand the company's cell therapy clinic services. However, the company continues to face financial challenges, as reflected in its negative profitability and reliance on the OTC market.
USRM OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that U.S. Stem Cell, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier typically involves higher risks for investors due to the potential for less transparency and greater price volatility.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Potential for low trading volume and liquidity.
- Increased price volatility due to OTC listing.
- Higher risk of fraud or manipulation compared to listed exchanges.
- Dependence on external funding to sustain operations.
- Verify the company's financial statements and SEC filings (if available).
- Assess the company's management team and their track record.
- Evaluate the company's intellectual property and competitive landscape.
- Review the company's clinical trial data and regulatory approvals.
- Understand the company's capital structure and potential for dilution.
- Monitor trading volume and price volatility.
- Consult with a qualified financial advisor.
- Focus on autologous cell therapies for chronic diseases.
- Ongoing clinical trials for MyoCell and AdipoCell.
- Operation of a cell therapy clinic providing cellular treatments.
- Provision of regenerative medicine training programs.
- Existence since 1999 suggests some level of operational history.
What Investors Ask About U.S. Stem Cell, Inc. (USRM) — Healthcare
What does U.S. Stem Cell, Inc. do?
U.S. Stem Cell, Inc. is a biotechnology company that develops and commercializes autologous cellular therapies for the treatment of chronic and acute heart damage, vascular diseases, and autoimmune conditions. Their lead product candidates include MyoCell, a therapy designed to regenerate damaged heart tissue, and AdipoCell, a therapy for treating myocardial infarction and ischemia.
What revenue streams does U.S. Stem Cell, Inc. have in healthcare?
U.S. Stem Cell, Inc.'s revenue streams include the sale of cell therapy products like MyoCell and AdipoCell (pending regulatory approvals), fees for regenerative medicine training programs offered to physicians and patients, revenue from cell collection and storage services for both human and animal applications, and income generated from their cell therapy clinic, which provides cellular treatments for various diseases. The relative contribution of each revenue stream is unknown.
What are the main risks for USRM?
The main risks for U.S. Stem Cell, Inc. include the potential for clinical trial failures, regulatory hurdles and approval delays, competition from larger biotechnology companies, limited financial resources and dependence on external funding, and the potential for dilution from future capital raises. Additionally, the company's OTC listing introduces risks related to liquidity, price volatility, and limited financial disclosure.
What are the key factors to evaluate for USRM?
Evaluate USRM on fundamentals, analyst consensus, and risk factors. U.S. Stem Cell, Inc. presents a high-risk, high-reward investment profile within the biotechnology sector. Not financial advice.
How frequently does USRM data refresh on this page?
USRM's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven USRM's recent stock price performance?
U.S. Stem Cell, Inc. (USRM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary autologous cell therapy technologies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider USRM overvalued or undervalued right now?
U.S. Stem Cell, Inc. (USRM) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research USRM before investing?
Before investing in U.S. Stem Cell, Inc. (USRM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited and may not be fully up-to-date.
- OTC market information may not be as reliable as data from listed exchanges.
- AI analysis pending for USRM, limiting comprehensive insights.